Friday 6 November 2026
Export RXST’s income statement to Excel — free account
RxSight, Inc.
RXST Healthcare Medical Devices
RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024.
- Revenue
- −19.0%
- EPS
- −62.1%
- Free cash flow
- +2,591.1%
Quarter to September 2026, against a year earlier
4.57
0.03
+0.66%
Follow RXST
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 3 | 3 |
+8 more TTM periods Free account |
| (20.10%) | (17.35%) | (17.06%) | (13.99%) | ||
| (16.44%) | (14.19%) | (15.12%) | (12.36%) | ||
ROIC |
(16,845.67%) | (63.16%) | (70.00%) | (63.34%) | |
Return on Tangible Assets |
(20.97%) | (17.99%) | (17.59%) | (14.20%) | |
Average Days of Receivables |
50.93 | 224.64 | 64.26 | 63.47 | |
Free Cash Flow per Share |
0.45 | (0.65) | (0.52) | (0.47) | |
Free Cash Flow |
18.65 | (27.16) | (21.58) | (19.34) | |
Capital Expenditures |
(5.03) | (4.43) | (4.01) | (3.83) | |
| Other line items | |||||
Cash ROIC |
3.66% | (5.75%) | (4.45%) | (3.84%) | |
Accounts Receivable Turnover |
5.92 | 2.39 | 4.77 | 5.03 | |
Accounts Payable Turnover |
8.55 | 5.92 | 4.12 | 6.40 | |
Inventory Turnover |
0.85 | 0.92 | 1.00 | 1.18 | |
Average Days of Payables |
42.96 | 80.67 | 88.75 | 61.42 | |
Days of Inventory on Hand |
496.94 | 471.93 | 434.39 | 366.03 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
30.23% | 28.75% | 29.54% | 28.67% | |
Selling, General and Administrative Expense of Revenue |
96.34% | 91.95% | 90.89% | 83.77% | |
Share Based Compensation of Revenue |
25.33% | 24.56% | 25.43% | 23.51% | |
Interest Coverage |
(4,727.15) | (3,936.64) | (3,459.12) | (2,536.37) | |
Operating CF/Net income |
(0.44) | 0.48 | 0.38 | 0.40 | |
Depreciation/Fixed assets |
(0.24) | (0.29) | (0.35) | (0.40) | |
Capex/Depreciation |
1.43 | 1.10 | 0.86 | 0.73 | |
Revenue per Share |
2.92 | 3.07 | 3.09 | 3.29 | |
Operating CF per Share |
0.57 | (0.55) | (0.43) | (0.38) | |
Capex per Share |
(0.12) | (0.11) | (0.10) | (0.09) | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.03 |
Columns are period end dates · fundamentals updated 5 Nov 2026